Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+ Tumors

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Related Keywords

Stephenv Liu , ,Georgetown University ,Georgetown Lombardi Comprehensive Cancer Center ,Thoracic Oncology ,Developmental Therapeutics ,News ,Lung Cancer ,Os1 Positive Tumors ,Nvl 520 ,Zidesamtinib ,